Recombinant Human Angiopoietin-1 Protein Best Seller
R&D Systems, part of Bio-Techne | Catalog # 923-AN
Key Product Details
Source
NS0
Accession #
Structure / Form
Oligomer
Conjugate
Unconjugated
Applications
Bioactivity
Product Specifications
Source
Mouse myeloma cell line, NS0-derived human Angiopoietin-1 protein
Ser20-Phe498, with a C-terminal 6-His tag
Ser20-Phe498, with a C-terminal 6-His tag
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Ser20
Predicted Molecular Mass
56 kDa
SDS-PAGE
70 kDa, reducing conditions
Activity
Measured by its ability to inhibit serum deprivation induced apoptosis in HUVEC human umbilical vein endothelial cells. Kwak, H.J. et al. (1999) FEBS Letters 448:249.
The ED50 for this effect is 10-40 ng/mL in the presence of 5 µg/mL of a
cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050).
The ED50 for this effect is 10-40 ng/mL in the presence of 5 µg/mL of a
cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050).
Reviewed Applications
Read 6 reviews rated 4.5 using 923-AN in the following applications:
Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 923-AN
| Formulation | Lyophilized from a 0.2 μm filtered solution in Tris-Citrate and NaCl with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 10 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 923-AN/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in Tris-Citrate and NaCl. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Angiopoietin-1
disulfide-linked homotrimers, tetramers, and pentamers (3, 5). Angiopoietin-1 binds and activates the receptor tyrosine kinase Tie-2, and its association into tetramers is important for full Tie-2 activation (3, 4). Angiopoietin-1 ligation of Tie-2 on vascular endothelial cells (EC) induces the development and branching of blood vessels (6, 7). In sub-confluent EC (i.e. during angiogenesis), Angiopoietin-1 promotes EC motility and Tie-2 localization at the trailing edge of the cell (8). In confluent EC (i.e. in homeostasis), multimeric Angiopoietin-1 enhances vascular integrity by promoting the in trans homotypic association of Tie-2 between EC or with the substratum (8, 9). In addition, Angiopoietin-1 suppresses several VEGF-induced effects on the vasculature including endothelial permeability, stretch-induced release of Angiopoietin-2, and up-regulation of the leukocyte adhesion molecules VCAM-1, ICAM-1, and E-Selectin (10-12). Angiopoietin-1 also interacts with a variety of integrins and the extracellular matrix independently of Tie-2 (13, 14). These interactions support the adhesion, migration and stress resistance of EC, fibroblasts, and myocytes (13, 14). Angiopoietin-1 can protect against pulmonary arterial hypertension (5), reduce the extent of fibrosis and remodeling in infarcted diabetic myocardium (15), and enhance tumor progression and metastasis (16).
References
- Koh, G.Y. (2012) Trends Mol. Med. 19:31.
- Suri, C. et al. (1996) Cell 87:1171.
- Davis, S. et al. (1996) Cell 87:1161.
- Kim, K.-T. et al. (2005) J. Biol. Chem. 280:20126.
- Kugathasan, L. et al. (2009) J. Exp. Med. 206:2221.
- Suri, C. et al. (1998) Science 282:468.
- Jeansson, M. et al. (2011) J. Clin. Invest. 121:2278.
- Saharinen, P. et al. (2008) Nat. Cell. Biol. 10:527.
- Fukuhara, S. et al. (2008) Nat. Cell Biol. 10:513.
- Jho, D. et al. (2005) Circ. Res. 96:1282.
- Korff, T. et al. (2012) Cardiovasc. Res. 94:510.
- Kim, I. et al. (2001) Circ. Res. 89:477.
- Carlson, T.R. et al. (2001) J. Biol. Chem. 276:26516.
- Dallabrida, S.M. et al. (2005) Cardiovasc. Res. 96:e8.
- Samuel, S.M. et al. (2010) Diabetes 59:51.
- Holopainen, T. et al. (2009) Cancer Res. 69:4656.
Alternate Names
ANGPT1
Gene Symbol
ANGPT1
UniProt
Additional Angiopoietin-1 Products
Product Documents for Recombinant Human Angiopoietin-1 Protein
Product Specific Notices for Recombinant Human Angiopoietin-1 Protein
For research use only
Loading...
Loading...
Loading...
Loading...